PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23538902-0	2013	Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.	XL 888	80-85	AKT serine/threonine kinase 1	Homo sapiens	20-23	
23538902-9	2013	In vivo, XL888 treatment led to degradation of CDK4 and Wee1 and the inhibition of AKT/S6 signaling with little or no effect observed upon ARAF, CRAF, or MAPK.	XL 888	9-14	AKT serine/threonine kinase 1	Homo sapiens	83-86